(Q38085441)

28 August 2017

title

Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia (English)

1 reference

28 August 2017

0 references

1

1 reference

28 August 2017

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

17 Suppl 1

1 reference

28 August 2017

page(s)

1-9

1 reference

Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Drug safety evaluation of ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine versus olanzapine in acute mania: a double-blind extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

7 January 2021

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

7 January 2021

Lurasidone in schizophrenia: new information about dosage and place in therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

7 January 2021

Atypical antipsychotics: matching receptor profile to individual patient's clinical profile

1 reference

https://api.crossref.org/works/10.1017%2FS1092852912000727

7 January 2021

10.1017/S1092852912000727

Identifiers

DOI

1 reference

28 August 2017

1 reference